ANXA9 gene expression in colorectal cancer: A novel marker for prognosis

Miyoshi,Norikatsu; Yamamoto,Hirofumi; Mimori,Koshi; Yamashita,Shinya; Miyazaki,Susumu; Nakagawa,Sumiko; Ishii,Hideshi; Noura,Shingo; Ohue,Masayuki; Yano,Masahiko; Doki,Yuichiro; Mori,Masaki

doi:10.3892/ol.2014.2477

ANXA9 gene expression in colorectal cancer: A novel marker for prognosis

Authors:
- Norikatsu Miyoshi
- Hirofumi Yamamoto
- Koshi Mimori
- Shinya Yamashita
- Susumu Miyazaki
- Sumiko Nakagawa
- Hideshi Ishii
- Shingo Noura
- Masayuki Ohue
- Masahiko Yano
- Yuichiro Doki
- Masaki Mori
View Affiliations

Affiliations: Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Osaka 537‑8511, Japan, Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565‑0871, Japan, Department of Molecular and Cellular Biology, Division of Molecular and Surgical Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Õhita 874‑0838, Japan, Department of Surgery, National Hospital Organization Kure Medical Center, Kure, Hiroshima 737‑0023, Japan, Department of Surgery, Osaka General Medical Center, Osaka, Osaka 558‑8558, Japan, Department of Frontier Science for Cancer and Chemotherapy, Osaka University, Suita, Osaka 565‑0871, Japan
Published online on: August 25, 2014 https://doi.org/10.3892/ol.2014.2477
Pages: 2313-2317

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Annexin A9 (ANXA9) is involved with the interaction with membrane phospholipids in a Ca2+‑dependent manner. A previous study has shown that ANXA9 expression is associated with bone metastasis in breast cancer, whereas its significance in colorectal cancer (CRC) is unknown. The present study was comprised of 100 patients who underwent surgery for CRC. The correlation between gene expression and the clinical parameters of the patients was assessed. Patients with high ANXA9 expression were statistically susceptible to a relatively worse prognosis, and those with low ANXA9 expression showed improved overall survival compared with those with high expression. In conclusion, the present data suggests that ANXA9 expression is a prognostic factor in CRC patients.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010.
2	Stein U and Schlag PM: Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res. 176:61–80. 2007.
3	Goebeler V, Ruhe D, Gerke V and Rescher U: Atypical properties displayed by annexin A9, a novel member of the annexin family of Ca(2+) and lipid binding proteins. FEBS Lett. 546:359–364. 2003.
4	Hawkins TE, Merrifield CJ and Moss SE: Calcium signaling and annexins. Cell Biochem Biophys. 33:275–296. 2000.
5	Gerke V and Moss SE: Annexins: from structure to function. Physiol Rev. 82:331–371. 2002.
6	Smid M, Wang Y, Klijn JG, et al: Genes associated with breast cancer metastatic to bone. J Clin Oncol. 24:2261–2267. 2006.
7	Watanabe T, Itabashi M, Shimada Y, et al: Japanese Society for Cancer of the Colon and Rectum: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 17:1–29. 2012.
8	Sobin LH and Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 80:1803–1804. 1997.
9	Mimori K, Mori M, Shiraishi T, et al: Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer. 76:531–536. 1997.
10	Mori M, Staniunas RJ, Barnard GF, et al: The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterology. 105:820–826. 1993.
11	Fava RA and Cohen S: Isolation of a calcium-dependent 35-kilodalton substrate for the epidermal growth factor receptor/kinase from A-431 cells. J Biol Chem. 259:2636–2645. 1984.
12	Huang KS, Wallner BP, Mattaliano RJ, et al: Two human 35 kd inhibitors of phospholipase A2 are related to substrates of pp60v-src and of the epidermal growth factor receptor/kinase. Cell. 46:191–199. 1986.
13	Morgan RO, Bell DW, Testa JR and Fernandez MP: Human annexin 31 genetic mapping and origin. Gene. 227:33–38. 1999.
14	Morgan RO and Fernández MP: Molecular phylogeny of annexins and identification of a primitive homologue in Giardia lamblia. Mol Biol Evol. 12:967–979. 1995.
15	Morgan RO and Fernandez MP: Annexin gene structures and molecular evolutionary genetics. Cell Mol Life Sci. 53:508–515. 1997.
16	Braun EL, Kang S, Nelson MA and Natvig DO: Identification of the first fungal annexin: analysis of annexin gene duplications and implications for eukaryotic evolution. J Mol Evol. 47:531–543. 1998.
17	André T, Quinaux E, Louvet C, et al: Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 25:3732–3738. 2007.
18	Wolpin BM and Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology. 134:1296–1310. 2008.
19	Kornmann M, Formentini A, Ette C, et al: Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol. 34:1316–1321. 2008.
20	Bathe OF, Dowden S, Sutherland F, et al: Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer. 4:322004.
21	Sadanandam A, Lyssiotis CA, Homicsko K, et al: A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 19:619–625. 2013.
22	Iijima M, Kano Y, Nohno T and Namba M: Cloning of cDNA with possible transcription factor activity at the G1-S phase transition in human fibroblast cell lines. Acta Med Okayama. 50:73–77. 1996.
23	Hansen WJ, Cowan NJ and Welch WJ: Prefoldin-nascent chain complexes in the folding of cytoskeletal proteins. J Cell Biol. 145:265–277. 1999.
24	Hodgson G, Hager JH, Volik S, et al: Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet. 29:459–464. 2001.
25	Lacy AM, García-Valdecasas JC, Delgado S, et al: Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 359:2224–2229. 2002.
26	Weeks JC, Nelson H, Gelber S, et al: Clinical Outcomes of Surgical Therapy (COST) Study Group: Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA. 287:321–328. 2002.
27	Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 350:2050–2059. 2004.
28	Jayne DG, Guillou PJ, Thorpe H, et al: UK MRC CLASICC Trial Group: Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 25:3061–3068. 2007.
29	Koshariya M, Jagad RB, Kawamoto J, et al: An update and our experience with metastatic liver disease. Hepatogastroenterology. 54:2232–2239. 2007.